CD274 and neoplasm: In the DONIMI clinical trial, the PD-L1 score (PD-L1 Tumor Proportion Score) predicted the response to treatment: All patients with a baseline PD-L1 score > 50% had a pathological response, while of those with a 1–50% PD-L1 score, 58% had a pathological response, and in those with a baseline PD-L1 score < 1%, only 22% had a pathological response [40].